Summary

Europe Oral Antiviral Market is valued approximately USD 9.71 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 2.11% over the forecast period 2024-2032. Oral antivirals are medications designed to treat viral infections by inhibiting the replication of the virus within the body. Unlike some antiviral drugs that are administered through injections or infusions, oral antivirals are taken by mouth in the form of pills or capsules, making them convenient for patients to use. Furthermore, pharmaceutical companies continue to invest in research and development to introduce new and more effective oral antiviral drugs. Advancements in drug delivery mechanisms, formulations, and efficacy are gaining attention towards Europe Oral Antiviral Market.

The Europe Oral Antiviral Market is driven by increasing prevalence of viral infections such as influenza, herpes, and HIV/AIDS across the region is driving the demand for oral antiviral medications. This rising incidence is leading to a greater need for effective treatment options, thereby fueling market expansion. Additionally, advancements in pharmaceutical research and development are resulting in the introduction of novel oral antiviral drugs with improved efficacy and safety profiles. These innovative therapies are gaining traction among healthcare professionals and patients, further boosting market growth. Moreover, factors such as increasing healthcare expenditure, expanding healthcare infrastructure, and growing awareness about the importance of early diagnosis and treatment are also contributing to the uptake of Europe Oral Antiviral Market. However, stringent regulatory requirements imposed by health authorities for the approval and commercialization of new oral antiviral drugs is going to impede the overall demand for the market during the forecast period 2024-2032.

The key countries considered for the European Oral Antiviral Market study includes UK, Germany, France, Italy, Spain, and Rest of Europe. In 2023, Germany was the largest regional market in terms of revenue owing to factors such as rising healthcare expenditure, rising disease prevalence and rising product approval, and supportive government polices across the region. Additionally, Germany's proactive regulatory environment and investment in research and development support the continuous innovation and introduction of new antiviral therapies. Furthermore, the market in UK, on the other hand, is expected to develop at the fastest rate over the forecast period 2024-2032.

Major market player included in this report are:
Gilead Sciences Inc.
F. Hoffmann-La Roche AG
Novartis AG
GlaxoSmithKline plc (GSK)
Company 5
Company 6
Company 7
Company 8
Company 9
Company 10
The detailed segments and sub-segment of the market are explained below:

By Indication
Hepatitis
Human Immunodeficiency Virus (HIV)
Influenza
Others

By Drug Class
Protease inhibitors
Reverse transcriptase inhibitors
Others

By Distribution Channel
Hospital pharmacies
Drug store and retail pharmacies
Online providers
By Region:
Europe
UK
Germany
France
Spain
Italy
ROE

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and Country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

ページTOPに戻る

Table of Contents

Chapter 1. Europe Oral Antiviral Market Definition and Research Assumptions
1.1. Research Objective
1.2. Market Definition
1.3. Research Assumptions
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.3.3. Supply Side Analysis
1.3.3.1. Availability
1.3.3.2. Infrastructure
1.3.3.3. Regulatory Environment
1.3.3.4. Market Competition
1.3.3.5. Economic Viability (Consumer’s Perspective)
1.3.4. Demand Side Analysis
1.3.4.1. Regulatory frameworks
1.3.4.2. Technological Advancements
1.3.4.3. Environmental Considerations
1.3.4.4. Consumer Awareness & Acceptance
1.4. Estimation Methodology
1.5. Years Considered for the Study
1.6. Currency Conversion Rates

Chapter 2. Executive Summary
2.1. Europe Oral Antiviral Market Size & Forecast (2022- 2032)
2.2. Regional Summary
2.3. Segmental Summary
2.3.1. By Indication
2.3.2. By Drug Class
2.3.3. By Distribution Channel
2.4. Key Trends
2.5. Recession Impact
2.6. Analyst Recommendation & Conclusion
Chapter 3. Europe Oral Antiviral Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
Chapter 4. Europe Oral Antiviral Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Europe Oral Antiviral Market Size & Forecasts by Indication 2022-2032
5.1. Hepatitis
5.2. Human Immunodeficiency Virus (HIV)
5.3. Influenza
5.4. Others
Chapter 6. Europe Oral Antiviral Market Size & Forecasts by Drug Class 2022-2032
6.1. Protease inhibitors
6.2. Reverse transcriptase inhibitors
6.3. Others
Chapter 7. Europe Oral Antiviral Market Size & Forecasts by Distribution Channel 2022-2032
7.1. Hospital pharmacies
7.2. Drug store and retail pharmacies
7.3. Online providers
Chapter 8. Europe Oral Antiviral Market Size & Forecasts by Country 2022-2032
8.1. U.K. Oral Antiviral Market
8.1.1. Indication breakdown size & forecasts, 2022-2032
8.1.2. Drug Class breakdown size & forecasts, 2022-2032
8.1.3. Distribution Channel breakdown size & forecasts, 2022-2032
8.2. Germany Oral Antiviral Market
8.3. France Oral Antiviral Market
8.4. Spain Oral Antiviral Market
8.5. Italy Oral Antiviral Market
8.6. Rest of Europe Oral Antiviral Market
Chapter 9. Competitive Intelligence
9.1. Key Company SWOT Analysis
9.1.1. Company 1
9.1.2. Company 2
9.1.3. Company 3
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. Gilead Sciences Inc.
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Market Strategies
9.3.2. F. Hoffmann-La Roche AG
9.3.3. Novartis AG
9.3.4. GlaxoSmithKline plc (GSK)
9.3.5. Company 5
9.3.6. Company 6
9.3.7. Company 7
9.3.8. Company 8
9.3.9. Company 9
9.3.10. Company 10
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes